Large biopharma firms have spent billions in 2025 on companies developing in vivo CAR‑T approaches as first human data arrive, and separate teams reported methods for mass production of CAR‑engineered iNK cells to enable scalable off‑the‑shelf immunotherapies. Industry reporting and company releases detail deal terms, early clinical readouts and manufacturing advances. Lead sentence: The market is channeling heavy capital into in vivo engineering and scalable engineered‑NK manufacturing after firms sign multibillion‑dollar partnerships and acquisitions to secure platforms that promise simpler delivery and industrialized supply chains. BioCentury and other outlets catalog deal activity and strategic rationale. Developers now face a twofold technical challenge: validate on‑target clinical efficacy and demonstrate manufacturing quality and safety at scale. For investors and corporate development teams, the combination of clinical momentum and new production methods—like processes described for CAR‑iNK mass production—reshapes commercial calculus for cell‑based immunotherapies.